Toll Free: 1-888-928-9744

Octapharma AG - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Octapharma AG - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Octapharma AG - Product Pipeline Review - 2015', provides an overview of the Octapharma AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Octapharma AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Octapharma AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Octapharma AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Octapharma AG's pipeline products

Reason To Buy 

- Evaluate Octapharma AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Octapharma AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Octapharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Octapharma AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Octapharma AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Octapharma AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Octapharma AG Snapshot 5 Octapharma AG Overview 5 Key Information 5 Key Facts 5 Octapharma AG - Research and Development Overview 6 Key Therapeutic Areas 6 Octapharma AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Octapharma AG - Pipeline Products Glance 10 Octapharma AG - Late Stage Pipeline Products 10 Pre-Registration Products/Combination Treatment Modalities 10 Phase III Products/Combination Treatment Modalities 11 Octapharma AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Octapharma AG - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Octapharma AG - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 Octapharma AG - Drug Profiles 15 coagulation factor VIII (recombinant) 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 plasma (human) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 fibrinogen concentrate (human) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 immune globulin (human) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 NewNorm 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 filgrastim 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Human Growth Factor 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Octapharma AG - Pipeline Analysis 26 Octapharma AG - Pipeline Products by Target 26 Octapharma AG - Pipeline Products by Route of Administration 27 Octapharma AG - Pipeline Products by Molecule Type 28 Octapharma AG - Pipeline Products by Mechanism of Action 29 Octapharma AG - Recent Pipeline Updates 30 Octapharma AG - Dormant Projects 32 Octapharma AG - Company Statement 33 Octapharma AG - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Octapharma AG - Key Manufacturing Facilities 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Octapharma AG, Key Information 5 Octapharma AG, Key Facts 5 Octapharma AG - Pipeline by Indication, 2015 7 Octapharma AG - Pipeline by Stage of Development, 2015 8 Octapharma AG - Monotherapy Products in Pipeline, 2015 9 Octapharma AG - Pre-Registration, 2015 10 Octapharma AG - Phase III, 2015 11 Octapharma AG - Phase II, 2015 12 Octapharma AG - Preclinical, 2015 13 Octapharma AG - Unknown, 2015 14 Octapharma AG - Pipeline by Target, 2015 26 Octapharma AG - Pipeline by Route of Administration, 2015 27 Octapharma AG - Pipeline by Molecule Type, 2015 28 Octapharma AG - Pipeline Products by Mechanism of Action, 2015 29 Octapharma AG - Recent Pipeline Updates, 2015 30 Octapharma AG - Dormant Developmental Projects,2015 32 Octapharma AG, Other Locations 35 Octapharma AG, Subsidiaries 36 Octapharma AG, Key Manufacturing Facilities 38



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify